Compare Stocks → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CARANASDAQ:DVAXNASDAQ:RTRXNASDAQ:STOKNASDAQ:TCDA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$0.66-4.2%$0.82$0.50▼$4.67$36.13M0.7663,525 shs350,663 shsDVAXDynavax Technologies$11.80+4.1%$12.35$10.06▼$15.15$1.54B1.262.04 million shs9.29 million shsRTRXTravere Therapeutics$5.80-3.2%$26.56$8.98▼$24.96$296.10M0.67412,277 shs972,749 shsSTOKStoke Therapeutics$12.05+3.4%$8.62$3.35▼$16.40$557.92M0.77976,811 shs1.01 million shsTCDATricida$0.13$0.09▼$13.85$6.01M0.2217.62 million shs31.13 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics-5.72%-14.88%-22.47%+22.12%-83.57%DVAXDynavax Technologies-0.79%-5.58%-5.66%-18.71%+3.75%RTRXTravere Therapeutics-3.17%-13.30%-22.46%-33.64%-72.78%STOKStoke Therapeutics-0.60%-13.70%+100.86%+136.31%+29.30%TCDATricida0.00%0.00%0.00%0.00%0.00%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.931 of 5 stars3.42.00.04.22.01.71.3DVAXDynavax Technologies4.2944 of 5 stars3.41.00.04.72.52.51.9RTRXTravere TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASTOKStoke Therapeutics4.1537 of 5 stars4.41.00.04.83.11.70.0TCDATricidaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics2.75Moderate Buy$9.751,375.04% UpsideDVAXDynavax Technologies2.75Moderate Buy$25.00111.86% UpsideRTRXTravere TherapeuticsN/AN/AN/AN/ASTOKStoke Therapeutics2.78Moderate Buy$19.6362.86% UpsideTCDATricidaN/AN/AN/AN/ACurrent Analyst RatingsLatest TCDA, DVAX, RTRX, STOK, and CARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.004/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/4/2024STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight3/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/26/2024STOKStoke TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$13.00 ➝ $17.003/26/2024STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $22.003/26/2024STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/26/2024STOKStoke TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/26/2024STOKStoke TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.00 ➝ $13.003/26/2024STOKStoke TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$20.97M1.72N/AN/A$1.05 per share0.63DVAXDynavax Technologies$232.28M6.65N/AN/A$4.81 per share2.45RTRXTravere Therapeutics$175.34M1.69N/AN/A$5.15 per share1.13STOKStoke Therapeutics$8.78M63.54N/AN/A$3.57 per share3.38TCDATricidaN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)DVAXDynavax Technologies-$6.39M-$0.06N/A27.44N/A-2.75%-1.08%-0.66%5/7/2024 (Estimated)RTRXTravere Therapeutics-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/ASTOKStoke Therapeutics-$104.70M-$2.37N/AN/AN/AN/A-56.86%-41.59%5/2/2024 (Estimated)TCDATricida-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/ALatest TCDA, DVAX, RTRX, STOK, and CARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2024Q4 2023STOKStoke Therapeutics-$0.62-$0.60+$0.02-$0.60$3.70 million$2.80 million3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.544.43DVAXDynavax Technologies0.4113.8112.96RTRXTravere Therapeutics0.667.237.14STOKStoke TherapeuticsN/A6.996.99TCDATricidaN/A4.874.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%DVAXDynavax Technologies96.96%RTRXTravere TherapeuticsN/ASTOKStoke TherapeuticsN/ATCDATricidaN/AInsider OwnershipCompanyInsider OwnershipCARACara Therapeutics4.20%DVAXDynavax Technologies2.62%RTRXTravere Therapeutics4.63%STOKStoke Therapeutics12.30%TCDATricida35.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics5554.66 million52.36 millionOptionableDVAXDynavax Technologies408130.86 million127.43 millionOptionableRTRXTravere Therapeutics22151.05 millionN/ANot OptionableSTOKStoke Therapeutics11046.30 million40.61 millionOptionableTCDATricida5755.67 million35.85 millionNot OptionableTCDA, DVAX, RTRX, STOK, and CARA HeadlinesSourceHeadlineSierraConstellation Partners Receives Industry Recognition for Work with Tricidafinance.yahoo.com - February 6 at 10:02 AMTricida Inc (TCDAQ)es.investing.com - January 13 at 10:29 AMEmerging Therapies in the Treatment of Clostridium difficile-Associated Diseasemedscape.com - May 30 at 8:27 AMVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo Financenews.google.com - April 18 at 12:45 AMMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital Journalnews.google.com - April 17 at 7:44 PMReal-time PCR as a Diagnostic Tool for Bacterial Diseasesmedscape.com - April 12 at 11:47 PMChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital Journalnews.google.com - April 10 at 8:38 AMChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital Journalnews.google.com - April 6 at 7:54 AMTricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360news.google.com - March 24 at 11:19 PMAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo Financenews.google.com - March 14 at 3:50 PMAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo Financenews.google.com - March 14 at 10:49 AMTricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360news.google.com - March 6 at 10:59 PMTroubled Adamis To Merge With Private DMK, Focus On ... - Scripnews.google.com - March 1 at 12:17 PMRelease Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360news.google.com - February 27 at 8:43 PMRenibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360news.google.com - February 21 at 8:22 PMSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comnews.google.com - February 18 at 1:53 AMTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comnews.google.com - February 18 at 1:53 AMTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - February 14 at 7:22 PMRising Serum Bicarbonate Lowers CKD Progression Risk in ... - Renal and Urology Newsnews.google.com - February 8 at 7:43 AMFirm Retention Summary: Tricida Inc.wsj.com - February 3 at 3:38 PMTricida's Chapter 11 Liquidation – Global Legal Chronicle - Global Legal Chroniclenews.google.com - January 29 at 8:47 AMTricida Gets OK To Seek Stalking Horse For Ch. 11 Auction - Law360news.google.com - January 26 at 6:43 PMWeak Fundamental Momentum Drags Tricida Inc. (TCDA) Lower - Marketing Sentinelnews.google.com - January 24 at 2:09 PMTricida Inc. (TCDA): This Stock is set to Soar Above its Peers - Invest Chroniclenews.google.com - January 24 at 9:08 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Dynavax TechnologiesNASDAQ:DVAXDynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Travere TherapeuticsNASDAQ:RTRXTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.Stoke TherapeuticsNASDAQ:STOKStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.TricidaNASDAQ:TCDATricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.